Oligoastrocytoma secondary prevention: Difference between revisions
(Created page with "__NOTOC__ {{Oligoastrocytoma}} {{CMG}}{{AE}}{{SR}} ==Overview== Patients treated for oligoastrocytoma should follow-up for secondary prevention. Secondary prevention strateg...") |
No edit summary |
||
| Line 10: | Line 10: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
===Follow up after treatment=== | ===Follow up after treatment=== | ||
Patients treated for | Patients treated for oligoastrocytoma should follow-up for secondary prevention. Follow-up measures are shown in the table below:<ref name="pmid23946171">{{cite journal| author=Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ et al.| title=Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 8 | pages= 917-23 | pmid=23946171 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23946171 }} </ref> | ||
*Clinical assessment of [[neurology|neurological function]] | |||
*Tapering [[steroid]] usage as early as possible | |||
*Checking for signs of [[venous thromboembolism]] | |||
*Laboratory tests | |||
**Generally not indicated, unless patient is on [[chemotherapy]] ([[complete blood count]]), [[steroids]] ([[glucose]] level), and [[anticonvulsants]] (complete blood count and [[liver function tests]]) | |||
*MRI every 3-4 months | |||
*[[PET|Positron emission tomography]] | |||
**To differentiate [[tumor]] recurrence from radiation-induced tumor [[necrosis]] | |||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center | {| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center | ||
|valign=top| | |valign=top| | ||
| Line 19: | Line 27: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | ||
: | :Clinical assessment of neurological function | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | ||
Revision as of 14:43, 19 October 2015
|
Oligoastrocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oligoastrocytoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Oligoastrocytoma secondary prevention |
|
Risk calculators and risk factors for Oligoastrocytoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Patients treated for oligoastrocytoma should follow-up for secondary prevention. Secondary prevention strategies following oligoastrocytoma include a clinical assessment of neurological function and corticosteroid use (Macdonald criteria), routine imaging (MRI and Positron Emission Tomography) at scheduled intervals after treatment. Secondary prevention measures of nasopharyneal cancer include routine physical examination and imaging at scheduled intervals after treatment. Dental screening and screening for thyroid cancers are recommended among patients who had received radiation therapy to the oral cavity and cervical region, respectively.
Secondary Prevention
Follow up after treatment
Patients treated for oligoastrocytoma should follow-up for secondary prevention. Follow-up measures are shown in the table below:[1]
- Clinical assessment of neurological function
- Tapering steroid usage as early as possible
- Checking for signs of venous thromboembolism
- Laboratory tests
- Generally not indicated, unless patient is on chemotherapy (complete blood count), steroids (glucose level), and anticonvulsants (complete blood count and liver function tests)
- MRI every 3-4 months
- Positron emission tomography
| Follow up | Description |
|---|---|
|
|
|
|
|
Scans are performed at routine intervals as follows:
|
|
|
|
|
Table adapted from Pfister DG, et al. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11(8):917-23.[1]
References
- ↑ 1.0 1.1 Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ; et al. (2013). "Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines". J Natl Compr Canc Netw. 11 (8): 917–23. PMID 23946171.